Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Vitale, M. Lanza, G. Calabrese, G. Caccavo, M. D'Amato, A. A. Stanziola (Naples, Italy). Idiopathic pulmonary fibrosis treatment: Combined pirfenidone + acetylcysteine vs N-acetylcysteine in monotherapy. Eur Respir J 2014; 44: Suppl. 58, 4502

Member's Comments

No comment yet.

Related content which might interest you: Effect of baseline statin use on benefit of nintedanib Source: International Congress 2016 – IPF treatment II Year: 2016 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 LATE-BREAKING ABSTRACT: Safety and tolerability of N-acetylcysteine (NAC) with pirfenidone in idiopathic pulmonary fibrosis (IPF): PANORAMA Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 High-dose N-acetylcysteine (NAC) in fibrotic interstitial lung diseases, a retrospective analysis Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Late Breaking Abstract - Pharmacokinetics (PK) of nintedanib with add-on pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): results from INJOURNEY Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 Tolerance of pirfenidone in Indian patients with idiopathic pulmonary fibrosis – Usual interstial pneumonitis: An initial experience Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Clinical experience with nintedanib for the treatment of IPF in 80 cases Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Safety and efficacy of pirfenidone in patients with lung fibrosis and TERT mutation Source: International Congress 2016 – IPF pathogenesis Year: 2016 LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis Source: Eur Respir J, 52 (2) 1800230; 10.1183/13993003.00230-2018 Year: 2018 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Pirfenidone post-authorization safety registry (PASSPORT) update Source: International Congress 2015 – Treatment of IPF Year: 2015 Effect of anti-acid medication on reduction in FVC decline with nintedanib Source: International Congress 2015 – Treatment of IPF Year: 2015 Effect of baseline composite physiologic index on benefit of nintedanib in IPF Source: International Congress 2016 – IPF treatment I Year: 2016 Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone Source: International Congress 2016 – Orphan diseases II Year: 2016 All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013